Blood-cell markers of inflammation are elevated in children with Cushing’s syndrome and may offer useful diagnostic information, say researchers.
The 3-year findings of the REAL 3 trial show that weekly somapacitan continued to deliver equivalent height gains and safety results to that achieved with standard daily recombinant human growth hormone treatment in children with growth hormone deficiency.
Treatment with recombinant human growth hormone is not associated with cardiovascular adverse events in clinical practice, show data from two large, multicentre cohorts.
Young children with short stature due to aggrecan deficiency achieve a marked improvement in height velocity during their first year of treatment with recombinant human growth hormone, shows a cohort study.
The likelihood of finding an underlying genetic cause of short stature in children is markedly increased if they have additional factors such as dysmorphic facial features or skeletal dysplasia, say researchers.
The evaluation of children presenting with short stature includes detailed clinical, phenotypic, auxological and biochemical assessments with genetic analyses in selected cases.
Recombinant human growth hormone appears to have a positive effect on growth in children with Kabuki Syndrome, shows an open-label study.
Programme Director Professor Martin Savage is joined by experts to present and discuss the application of precision medicine in endocrine disorders, offering clinical expertise and insight, evidence and opinion on this topic.
Children with Cushing’s disease who have a negative magnetic resonance imaging pituitary scan are less likely to achieve remission after surgery than those with a confirmed tumour, say researchers.
A cohort study of healthy infants has characterised the relationships between circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 and changes in body length and weight in the first year of life.
